Antibodies for bioanalysis and drug monitoring of ustekinumab and biosimilars

Develop highly selective and sensitive PK and ADA assays for ustekinumab (Stelara) using our range of ready-made anti-idiotypic antibodies.

  • Inhibitory antibodies specific to ustekinumab
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch to batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Ustekinumab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Ustekinumab

Inhibitory Type 1

HCA208

AbD17829

Fab-V5Sx21

2.8

PK bridging ELISA

Order HCA208

HCA209

AbD18334

Fab-FH2

0.4

PK bridging ELISA

Order HCA209

HCA210
HCA210P

AbD17827_hIgG1

hIgG1

HRP

0.2

PK bridging ELISA

ADA control

Order HCA210
Order HCA210P

HCA211

AbD17829_hIgG1

hIgG1

2.8

ADA control

Order HCA211

* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody, V5- and StrepX-StrepX- tags

2 Monovalent Fab antibody DYKDDDDK- and His-6-tags


Anti-Ustekinumab Inhibitory Antibodies (Type 1)

Type 1 anti-ustekinumab antibodies inhibit the binding of the drug ustekinumab to its targets, human interleukin 12 (IL-12) and interleukin 23 (IL-23). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are available in two affinities, and are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.


ELISA Protocols to Get You Started

PK Bridging ELISA


Fig. 1. Ustekinumab PK bridging ELISA using antibodies HCA209 and HCA210P.

Fig. 1. Ustekinumab PK bridging ELISA using antibodies HCA209 and HCA210P.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.


ADA Bridging ELISA


Fig. 2. Ustekinumab ADA bridging ELISA using antibody HCA210 or HCA211.

Fig. 2. Ustekinumab ADA bridging ELISA using antibody HCA210 or HCA211.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).


Related Products



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.